SCHEMBL25320265

SCHEMBL25320265

CCCCCCCCCCN(CCCCCCCCCC)C(=O)C(F)CCCCCCN(CCCCCO)CCCCCCC(F)C(=O)N(CCCCCCCCCC)CCCCCCCCCC

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.47
ZDHHC20 Q5W0Z9 1/20 0.38
ZDHHC2 Q9UIJ5 1/20 0.38
LMNA P02545 2/20 0.38
ALDH1A1 P00352 1/20 0.38
HSD17B10 Q99714 1/20 0.38
MEN1 O00255 1/20 0.38
KMT2A Q03164 1/20 0.38
TSHR P16473 1/20 0.38
KDM5A P29375 2/20 0.35
PHF8 Q9UPP1 2/20 0.35
KDM4C Q9H3R0 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CA12 O43570 2/20 0.35
CA1 P00915 2/20 0.35
CA9 Q16790 2/20 0.35
SPHK1 Q9NYA1 1/20 0.34
GPR84 Q9NQS5 2/20 0.34
CA2 P00918 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25234043 0.85 MAPT (0.50) MAPTZDHHC20ZDHHC2CA12CA1
SCHEMBL25320247 0.83 MAPT (0.51) MAPTZDHHC20ZDHHC2KDM5APHF8
SCHEMBL31196407 0.79 MAPT (0.39) MAPTZDHHC20ZDHHC2KDM5APHF8
SCHEMBL1404090 0.75 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL4937294 0.75 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL8053580 0.75 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL23888725 0.75 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
Octanol SCHEMBL22656886 0.75 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL9807808 0.75 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A
SCHEMBL1404085 0.75 LMNA (0.68) LMNAALDH1A1HSD17B10MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250188020-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS ACUITAS THERAPEUTICS INC (CA) 2025-06-12 US disclosed
US-20250059131-A1 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES ACUITAS THERAPEUTICS INC (CA) 2025-02-20 US disclosed
US-12129223-B2 Lipids for use in lipid nanoparticle formulations Acuitas Therapeutics, Inc. (CA) 2024-10-29 US disclosed
EP-4448482-A2 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES Acuitas Therapeutics, Inc. (CA) 2024-10-23 EP disclosed
EP-4448485-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2024-10-23 EP disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-09-21 US disclosed
WO-2023114943-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed
WO-2023114943-A2 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed
WO-2023114937-A2 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed
WO-2023114937-A2 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES Acuitas Therapeutics, Inc. (CA) 2023-06-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230295075-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS PHOSPHO1, SGMS1, NPC1 MAPT 14/4885ZDHHC20 1460/4885ZDHHC2 566/4885
US-20250059131-A1 FLUORINATED CATIONIC LIPIDS FOR USE IN LIPID NANOPARTICLES PHOSPHO1, NPC1, SGMS1 MAPT 19/4885ZDHHC20 1428/4885ZDHHC2 757/4885
US-20250188020-A1 LIPIDS FOR USE IN LIPID NANOPARTICLE FORMULATIONS PHOSPHO1, SGMS1, NPC1 MAPT 14/4885ZDHHC20 1460/4885ZDHHC2 566/4885
US-12129223-B2 Lipids for use in lipid nanoparticle formulations PHOSPHO1, SGMS1, NPC1 MAPT 14/4885ZDHHC20 1460/4885ZDHHC2 566/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.